根据 7 位华尔街分析师的预测,KORU Medical Systems Inc 的收入预期范围从 $12.62M 到 $11.27M
KORU Medical Systems Inc 的盈利质量评分是多少?
KORU Medical Systems Inc 的盈利质量评分为 B+/55.332573。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
KORU Medical Systems Inc 何时发布财报?
KORU Medical Systems Inc 的下一份财报预计在 2026-06-10 发布
KORU Medical Systems Inc 的预期收益是多少?
根据华尔街分析师的预测,KORU Medical Systems Inc 的预期收益为 $
KORU Medical Systems Inc 是否超出收益预期?
KORU Medical Systems Inc 最近的收益为 $10.9M, 预期。
关键数据
前收盘价
$4.27
开盘价
$4.27
当日区间
$4.15 - $4.32
52周范围
$1.86 - $6.6
交易量
52.8K
平均成交量
189.3K
股息收益率
--
每股收益(TTM)
-0.06
市值
$200.3M
什么是 KRMD?
KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Mahwah, New Jersey and currently employs 73 full-time employees. The firm is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The firm is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.